Biological Sample Collection Kits Market by Product Type (Automated Systems, Multi Sample Kits, Single Use Kits), Sample Type (Blood, Saliva, Stool), Application, End User - Global Forecast 2025-2032
Description
The Biological Sample Collection Kits Market was valued at USD 9.31 billion in 2024 and is projected to grow to USD 10.13 billion in 2025, with a CAGR of 8.85%, reaching USD 18.36 billion by 2032.
Comprehensive orientation to biological sample collection kit dynamics highlighting technology, regulation, decentralization, and quality assurance drivers
Biological sample collection kits underpin a vast array of diagnostic, research, and therapeutic workflows, and their design, regulation, and distribution directly influence downstream data integrity and patient outcomes. Recent technological advances in preservatives, stabilization chemistry, and closed-system designs have reduced pre-analytical variability, enabling broader decentralization of sample collection and supporting both centralized laboratories and point-of-care settings. Regulatory scrutiny and quality expectations have risen in parallel, requiring vendors to demonstrate chain-of-custody controls, biomarker stability, and compatibility with automated processing platforms.
As stakeholders recalibrate procurement strategies, they consider not only cost and compatibility but also specimen integrity across transport conditions, cold-chain dependencies, and evolving privacy and consent frameworks. Investors and product development teams prioritize kits that enable scalable workflows while minimizing technician touchpoints, as these attributes materially affect throughput and reproducibility. Consequently, organizations that align product engineering with laboratory automation, digital tracking, and regulatory readiness are positioned to capture greater clinical and research adoption over time.
How automation, decentralization, digital tracking, and regulatory emphasis are jointly reshaping product requirements and distribution models across the industry
The landscape for biological sample collection has shifted markedly as technology, clinical practice, and distribution models converge to reshape adoption pathways. Automation advancement has reduced manual handling and standardized specimen preparation, thereby decreasing sample-to-sample variability and accelerating laboratory throughput. Concurrently, consumer-facing collection models have expanded; remote and at-home sample collection programs now support longitudinal clinical trials, telehealth diagnostics, and population-level screening, increasing the variety of user profiles and demand for clearer instructions and tamper-evident design.
Moreover, integration with digital health tools and sample tracking systems has enhanced traceability, enabling more reliable chain-of-custody and real-time status updates during transport. Regulatory emphasis on pre-analytical variables and biospecimen integrity has prompted manufacturers to incorporate robust stabilization chemistries and validated transport conditions. Together, these factors are catalyzing a move from point-products toward platform solutions that offer interoperability with laboratory analyzers, data management systems, and regulatory documentation workflows, ultimately elevating expectations for vendors across the value chain.
Assessment of the 2025 tariff landscape and its cumulative influence on sourcing strategy, supply resilience, and compliance imperatives for kit manufacturers
Tariff changes implemented in 2025 have introduced new operational considerations for manufacturers, distributors, and end users of biological sample collection kits, affecting supply chain economics and procurement strategies. In practice, increased duties on imported components have incentivized manufacturers to reassess regional sourcing, seek alternative suppliers, and accelerate qualification of local vendors in order to mitigate cost exposure and avoid disruption to production schedules. This shift has also spurred greater investment in supplier redundancy and inventory buffers to maintain continuity for clinical trials and diagnostic laboratory contracts.
As a result, procurement teams are reevaluating total landed cost versus lead-time trade-offs and prioritizing suppliers with validated quality systems located in tariff-favored jurisdictions. At the same time, logistics providers have adapted by offering consolidated shipping and tariff-managed warehousing solutions that help harmonize cross-border flows. Regulatory affairs and quality teams must remain vigilant as supplier changes can introduce variability that affects validation and compliance documentation. Overall, the cumulative impact of tariffs in 2025 has prompted a strategic rebalancing of sourcing, manufacturing footprint, and inventory policies that emphasizes resilience and quality assurance across the supply chain.
Deep segmentation-driven implications for design, validation, and commercial approaches across specimen types, end users, product modalities, and application domains
Segmentation-driven insights illuminate opportunities and constraints across product development, go-to-market strategies, and clinical adoption. Based on Sample Type, product development teams must optimize designs for Blood, Saliva, Stool, Tissue, and Urine specimens, while addressing sub-type requirements such as Plasma, Serum, and Whole Blood for blood-derived assays, and FFPE Tissue, Fresh Tissue, and Frozen Tissue for tissue-based workflows. This differentiation drives distinct preservation needs, transport conditions, and compatibility with downstream analytical platforms.
Based on End User, commercial strategies should be tailored to Biopharma Companies, Diagnostic Laboratories, Home Healthcare providers, Hospitals, and Research Institutes, recognizing that each segment values different attributes such as regulatory support, batch consistency, user-friendliness, or cost per test. Based on Product Type, opportunities differ between Automated Systems that integrate into high-throughput laboratories, Multi Sample Kits designed for batch processing and cohort studies, and Single Use Kits intended for point collection or home use. Based on Application, clinical diagnostics, drug discovery, environmental monitoring, genetic testing, and infectious disease testing each impose unique performance criteria, regulatory pathways, and lab workflow integrations. Consequently, manufacturers that align product architecture and quality documentation with these layered segmentation demands are better positioned to address end-user constraints, accelerate validation cycles, and capture cross-segment adoption.
Regional dynamics and operational considerations highlighting procurement behaviors, regulatory diversity, and distribution models across major global territories
Regional nuances materially influence regulatory requirements, distribution channels, and customer expectations, requiring strategies that reflect local healthcare infrastructure and reimbursement environments. In the Americas, demand is driven by decentralized testing initiatives, broad clinical trial activity, and a substantial private laboratory network that favors scalable solutions with strong data integration and cold-chain flexibility. Regulatory agencies and large diagnostic customers in this region emphasize demonstrable clinical equivalence and streamlined documentation to support rapid deployment across diverse settings.
In the Europe, Middle East & Africa region, heterogeneity in regulatory frameworks and healthcare funding models necessitates modular strategies that balance centralized certification with localized regulatory submissions and translation of technical dossiers. Providers often prioritize interoperability with national laboratory information systems and robust biospecimen stability across long transport corridors. In Asia-Pacific, rapid adoption of digital health platforms, high-volume public health screening programs, and growing domestic manufacturing capabilities create opportunities for localized production, faster regulatory cycles in some markets, and increased emphasis on cost-effectiveness and logistical optimization. Collectively, these regional dynamics underscore the need for adaptable commercial frameworks and manufacturing footprints that can meet varied regulatory timelines and deployment models.
Competitive positioning and strategic capabilities firms are deploying to differentiate through product innovation, regulatory rigor, manufacturing scale, and partnership-driven market expansion
Leading companies in the sample collection ecosystem are advancing capabilities across R&D, manufacturing, and services to address the evolving demands of laboratories, clinics, and decentralized care models. Strategic differentiation often emerges from combinations of proprietary stabilization chemistries, patent-protected consumables, and software-enabled chain-of-custody solutions that facilitate integration into automated workflows. Firms that couple product innovation with rigorous quality systems and transparent validation data tend to secure enterprise-level contracts with diagnostic laboratories and biopharma sponsors.
Partnerships and strategic alliances are increasingly common as manufacturers seek to extend channel reach, validate compatibility with third-party analyzers, and co-develop solutions for specialized applications such as genetic testing or infectious disease surveillance. Meanwhile, investment in scalable manufacturing and regulatory affairs capabilities enables rapid response to demand fluctuations and local registration requirements. Consequently, competitive positioning now depends on a balanced portfolio that includes core consumables, high-throughput automation, and service offerings such as custom kit development and on-site validation support, ensuring that customers can operationalize solutions with minimal friction.
Concrete strategic actions that leaders can implement to optimize product alignment, supply resilience, digital integration, and regional commercialization effectiveness
To capture value and accelerate adoption, industry leaders should prioritize a set of actionable moves that strengthen product-market fit while enhancing operational resilience. First, align product development roadmaps with segmented user needs-design single use kits for ease of home collection, multi sample kits for cohort studies, and automated systems for centralized high-throughput laboratories-while ensuring that stabilization chemistries are validated for relevant specimen subtypes such as plasma, serum, FFPE, fresh, and frozen tissue. Second, diversify supplier networks and qualify regional contract manufacturers to mitigate tariff-driven cost pressures and reduce lead-time risk while maintaining rigorous quality oversight.
Third, invest in digital sample tracking and data integration to improve chain-of-custody, regulatory traceability, and interoperability with laboratory information management systems. Fourth, structure commercial models to reflect regional regulatory and procurement realities, offering bundled validation support, custom labeling, or local regulatory dossiers where required. Finally, forge collaborative partnerships with diagnostic labs, biopharma sponsors, and logistics providers to co-develop validated workflows, thereby lowering adoption barriers and accelerating clinical and research deployment. Implementing these steps will improve resilience, shorten time-to-validation, and enhance end-user confidence in deployed solutions.
Transparent mixed-methods research approach combining primary stakeholder engagement, technical dossier review, and scenario analysis to validate actionable conclusions
This research synthesis draws on a mixed-methods approach combining primary stakeholder interviews, technical documentation reviews, and supply chain mapping to ensure a comprehensive and verifiable view of industry dynamics. Primary inputs included structured conversations with laboratory directors, procurement leads, regulatory specialists, and product managers, supplemented by anonymized insights from logistics and manufacturing partners to validate lead-time and component sourcing constraints. These qualitative inputs were cross-referenced with product specifications, validation protocols, and standard regulatory guidance to assess design trade-offs and compliance implications.
In parallel, secondary research encompassed peer-reviewed literature, technical standards, and policy updates to ensure currency around stabilization technologies, specimen handling recommendations, and regulatory expectations. Synthesis employed thematic analysis to identify common challenges and success factors, followed by scenario testing to evaluate the operational impact of tariffs, supplier reconfigurations, and technological shifts. Throughout, emphasis was placed on reproducible methods, clear documentation of assumptions, and traceable chains of evidence so that recommendations can be adapted to specific organizational contexts or validated through additional primary engagement.
Synthesis of strategic implications emphasizing integration, supply resilience, regulatory readiness, and the transition toward interoperable platform solutions
The current trajectory of biological sample collection kit development emphasizes integration, reliability, and adaptability, as stakeholders seek solutions that lower pre-analytical risk while enabling broader testing access. Transitioning from discrete product offerings to interoperable platforms reduces friction in laboratory workflows and supports the scaling of decentralized testing models. At the same time, supply chain realignment in response to tariff changes and logistics constraints underscores the importance of supplier diversification and regional manufacturing agility.
Looking ahead, companies that couple robust validation data with digital traceability and flexible commercial frameworks will be best positioned to meet the diverse needs of biopharma sponsors, diagnostic laboratories, hospitals, home healthcare providers, and research institutes. By adopting a strategic posture that emphasizes quality systems, regulatory preparedness, and collaborative validation, stakeholders can accelerate adoption and reduce operational risk, enabling higher confidence in diagnostic results and research outputs alike.
Note: PDF & Excel + Online Access - 1 Year
Comprehensive orientation to biological sample collection kit dynamics highlighting technology, regulation, decentralization, and quality assurance drivers
Biological sample collection kits underpin a vast array of diagnostic, research, and therapeutic workflows, and their design, regulation, and distribution directly influence downstream data integrity and patient outcomes. Recent technological advances in preservatives, stabilization chemistry, and closed-system designs have reduced pre-analytical variability, enabling broader decentralization of sample collection and supporting both centralized laboratories and point-of-care settings. Regulatory scrutiny and quality expectations have risen in parallel, requiring vendors to demonstrate chain-of-custody controls, biomarker stability, and compatibility with automated processing platforms.
As stakeholders recalibrate procurement strategies, they consider not only cost and compatibility but also specimen integrity across transport conditions, cold-chain dependencies, and evolving privacy and consent frameworks. Investors and product development teams prioritize kits that enable scalable workflows while minimizing technician touchpoints, as these attributes materially affect throughput and reproducibility. Consequently, organizations that align product engineering with laboratory automation, digital tracking, and regulatory readiness are positioned to capture greater clinical and research adoption over time.
How automation, decentralization, digital tracking, and regulatory emphasis are jointly reshaping product requirements and distribution models across the industry
The landscape for biological sample collection has shifted markedly as technology, clinical practice, and distribution models converge to reshape adoption pathways. Automation advancement has reduced manual handling and standardized specimen preparation, thereby decreasing sample-to-sample variability and accelerating laboratory throughput. Concurrently, consumer-facing collection models have expanded; remote and at-home sample collection programs now support longitudinal clinical trials, telehealth diagnostics, and population-level screening, increasing the variety of user profiles and demand for clearer instructions and tamper-evident design.
Moreover, integration with digital health tools and sample tracking systems has enhanced traceability, enabling more reliable chain-of-custody and real-time status updates during transport. Regulatory emphasis on pre-analytical variables and biospecimen integrity has prompted manufacturers to incorporate robust stabilization chemistries and validated transport conditions. Together, these factors are catalyzing a move from point-products toward platform solutions that offer interoperability with laboratory analyzers, data management systems, and regulatory documentation workflows, ultimately elevating expectations for vendors across the value chain.
Assessment of the 2025 tariff landscape and its cumulative influence on sourcing strategy, supply resilience, and compliance imperatives for kit manufacturers
Tariff changes implemented in 2025 have introduced new operational considerations for manufacturers, distributors, and end users of biological sample collection kits, affecting supply chain economics and procurement strategies. In practice, increased duties on imported components have incentivized manufacturers to reassess regional sourcing, seek alternative suppliers, and accelerate qualification of local vendors in order to mitigate cost exposure and avoid disruption to production schedules. This shift has also spurred greater investment in supplier redundancy and inventory buffers to maintain continuity for clinical trials and diagnostic laboratory contracts.
As a result, procurement teams are reevaluating total landed cost versus lead-time trade-offs and prioritizing suppliers with validated quality systems located in tariff-favored jurisdictions. At the same time, logistics providers have adapted by offering consolidated shipping and tariff-managed warehousing solutions that help harmonize cross-border flows. Regulatory affairs and quality teams must remain vigilant as supplier changes can introduce variability that affects validation and compliance documentation. Overall, the cumulative impact of tariffs in 2025 has prompted a strategic rebalancing of sourcing, manufacturing footprint, and inventory policies that emphasizes resilience and quality assurance across the supply chain.
Deep segmentation-driven implications for design, validation, and commercial approaches across specimen types, end users, product modalities, and application domains
Segmentation-driven insights illuminate opportunities and constraints across product development, go-to-market strategies, and clinical adoption. Based on Sample Type, product development teams must optimize designs for Blood, Saliva, Stool, Tissue, and Urine specimens, while addressing sub-type requirements such as Plasma, Serum, and Whole Blood for blood-derived assays, and FFPE Tissue, Fresh Tissue, and Frozen Tissue for tissue-based workflows. This differentiation drives distinct preservation needs, transport conditions, and compatibility with downstream analytical platforms.
Based on End User, commercial strategies should be tailored to Biopharma Companies, Diagnostic Laboratories, Home Healthcare providers, Hospitals, and Research Institutes, recognizing that each segment values different attributes such as regulatory support, batch consistency, user-friendliness, or cost per test. Based on Product Type, opportunities differ between Automated Systems that integrate into high-throughput laboratories, Multi Sample Kits designed for batch processing and cohort studies, and Single Use Kits intended for point collection or home use. Based on Application, clinical diagnostics, drug discovery, environmental monitoring, genetic testing, and infectious disease testing each impose unique performance criteria, regulatory pathways, and lab workflow integrations. Consequently, manufacturers that align product architecture and quality documentation with these layered segmentation demands are better positioned to address end-user constraints, accelerate validation cycles, and capture cross-segment adoption.
Regional dynamics and operational considerations highlighting procurement behaviors, regulatory diversity, and distribution models across major global territories
Regional nuances materially influence regulatory requirements, distribution channels, and customer expectations, requiring strategies that reflect local healthcare infrastructure and reimbursement environments. In the Americas, demand is driven by decentralized testing initiatives, broad clinical trial activity, and a substantial private laboratory network that favors scalable solutions with strong data integration and cold-chain flexibility. Regulatory agencies and large diagnostic customers in this region emphasize demonstrable clinical equivalence and streamlined documentation to support rapid deployment across diverse settings.
In the Europe, Middle East & Africa region, heterogeneity in regulatory frameworks and healthcare funding models necessitates modular strategies that balance centralized certification with localized regulatory submissions and translation of technical dossiers. Providers often prioritize interoperability with national laboratory information systems and robust biospecimen stability across long transport corridors. In Asia-Pacific, rapid adoption of digital health platforms, high-volume public health screening programs, and growing domestic manufacturing capabilities create opportunities for localized production, faster regulatory cycles in some markets, and increased emphasis on cost-effectiveness and logistical optimization. Collectively, these regional dynamics underscore the need for adaptable commercial frameworks and manufacturing footprints that can meet varied regulatory timelines and deployment models.
Competitive positioning and strategic capabilities firms are deploying to differentiate through product innovation, regulatory rigor, manufacturing scale, and partnership-driven market expansion
Leading companies in the sample collection ecosystem are advancing capabilities across R&D, manufacturing, and services to address the evolving demands of laboratories, clinics, and decentralized care models. Strategic differentiation often emerges from combinations of proprietary stabilization chemistries, patent-protected consumables, and software-enabled chain-of-custody solutions that facilitate integration into automated workflows. Firms that couple product innovation with rigorous quality systems and transparent validation data tend to secure enterprise-level contracts with diagnostic laboratories and biopharma sponsors.
Partnerships and strategic alliances are increasingly common as manufacturers seek to extend channel reach, validate compatibility with third-party analyzers, and co-develop solutions for specialized applications such as genetic testing or infectious disease surveillance. Meanwhile, investment in scalable manufacturing and regulatory affairs capabilities enables rapid response to demand fluctuations and local registration requirements. Consequently, competitive positioning now depends on a balanced portfolio that includes core consumables, high-throughput automation, and service offerings such as custom kit development and on-site validation support, ensuring that customers can operationalize solutions with minimal friction.
Concrete strategic actions that leaders can implement to optimize product alignment, supply resilience, digital integration, and regional commercialization effectiveness
To capture value and accelerate adoption, industry leaders should prioritize a set of actionable moves that strengthen product-market fit while enhancing operational resilience. First, align product development roadmaps with segmented user needs-design single use kits for ease of home collection, multi sample kits for cohort studies, and automated systems for centralized high-throughput laboratories-while ensuring that stabilization chemistries are validated for relevant specimen subtypes such as plasma, serum, FFPE, fresh, and frozen tissue. Second, diversify supplier networks and qualify regional contract manufacturers to mitigate tariff-driven cost pressures and reduce lead-time risk while maintaining rigorous quality oversight.
Third, invest in digital sample tracking and data integration to improve chain-of-custody, regulatory traceability, and interoperability with laboratory information management systems. Fourth, structure commercial models to reflect regional regulatory and procurement realities, offering bundled validation support, custom labeling, or local regulatory dossiers where required. Finally, forge collaborative partnerships with diagnostic labs, biopharma sponsors, and logistics providers to co-develop validated workflows, thereby lowering adoption barriers and accelerating clinical and research deployment. Implementing these steps will improve resilience, shorten time-to-validation, and enhance end-user confidence in deployed solutions.
Transparent mixed-methods research approach combining primary stakeholder engagement, technical dossier review, and scenario analysis to validate actionable conclusions
This research synthesis draws on a mixed-methods approach combining primary stakeholder interviews, technical documentation reviews, and supply chain mapping to ensure a comprehensive and verifiable view of industry dynamics. Primary inputs included structured conversations with laboratory directors, procurement leads, regulatory specialists, and product managers, supplemented by anonymized insights from logistics and manufacturing partners to validate lead-time and component sourcing constraints. These qualitative inputs were cross-referenced with product specifications, validation protocols, and standard regulatory guidance to assess design trade-offs and compliance implications.
In parallel, secondary research encompassed peer-reviewed literature, technical standards, and policy updates to ensure currency around stabilization technologies, specimen handling recommendations, and regulatory expectations. Synthesis employed thematic analysis to identify common challenges and success factors, followed by scenario testing to evaluate the operational impact of tariffs, supplier reconfigurations, and technological shifts. Throughout, emphasis was placed on reproducible methods, clear documentation of assumptions, and traceable chains of evidence so that recommendations can be adapted to specific organizational contexts or validated through additional primary engagement.
Synthesis of strategic implications emphasizing integration, supply resilience, regulatory readiness, and the transition toward interoperable platform solutions
The current trajectory of biological sample collection kit development emphasizes integration, reliability, and adaptability, as stakeholders seek solutions that lower pre-analytical risk while enabling broader testing access. Transitioning from discrete product offerings to interoperable platforms reduces friction in laboratory workflows and supports the scaling of decentralized testing models. At the same time, supply chain realignment in response to tariff changes and logistics constraints underscores the importance of supplier diversification and regional manufacturing agility.
Looking ahead, companies that couple robust validation data with digital traceability and flexible commercial frameworks will be best positioned to meet the diverse needs of biopharma sponsors, diagnostic laboratories, hospitals, home healthcare providers, and research institutes. By adopting a strategic posture that emphasizes quality systems, regulatory preparedness, and collaborative validation, stakeholders can accelerate adoption and reduce operational risk, enabling higher confidence in diagnostic results and research outputs alike.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
194 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of smartphone-enabled barcoding and real-time tracking in sample collection kits to enhance chain of custody
- 5.2. Rising demand for noninvasive saliva and breath sampling kits in point-of-care diagnostic applications in remote settings
- 5.3. Development of ambient temperature stable reagents and transport media to simplify global sample logistics and reduce cold chain reliance
- 5.4. Adoption of modular microfluidic platforms in collection kits for multiplexed biomarker separation and stabilization at source
- 5.5. Use of artificial intelligence algorithms in pre-analytical quality control to detect sample contamination or insufficient volume before shipping
- 5.6. Expansion of DIY at-home genetic testing kits with simplified user interfaces and integrated e-commerce replenishment options
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Biological Sample Collection Kits Market, by Product Type
- 8.1. Automated Systems
- 8.2. Multi Sample Kits
- 8.3. Single Use Kits
- 9. Biological Sample Collection Kits Market, by Sample Type
- 9.1. Blood
- 9.1.1. Plasma
- 9.1.2. Serum
- 9.1.3. Whole Blood
- 9.2. Saliva
- 9.3. Stool
- 9.4. Tissue
- 9.4.1. FFPE Tissue
- 9.4.2. Fresh Tissue
- 9.4.3. Frozen Tissue
- 9.5. Urine
- 10. Biological Sample Collection Kits Market, by Application
- 10.1. Clinical Diagnostics
- 10.2. Drug Discovery
- 10.3. Environmental Monitoring
- 10.4. Genetic Testing
- 10.5. Infectious Disease Testing
- 11. Biological Sample Collection Kits Market, by End User
- 11.1. Biopharma Companies
- 11.2. Diagnostic Laboratories
- 11.3. Home Healthcare
- 11.4. Hospitals
- 11.5. Research Institutes
- 12. Biological Sample Collection Kits Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Biological Sample Collection Kits Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Biological Sample Collection Kits Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Abbott Laboratories
- 15.3.2. Agilent Technologies, Inc.
- 15.3.3. Avantor, Inc.
- 15.3.4. B. Braun SE
- 15.3.5. Becton, Dickinson, and Company
- 15.3.6. Bio-Rad Laboratories, Inc.
- 15.3.7. Biosigma S.p.A.
- 15.3.8. Cardinal Health, Inc.
- 15.3.9. Eurofins Scientific SE
- 15.3.10. Exelint International, Co.
- 15.3.11. F. Hoffmann-La Roche Ltd.
- 15.3.12. F.L. Medical S.r.l.
- 15.3.13. Globe Scientific Inc.
- 15.3.14. Greiner AG
- 15.3.15. Haemonetics Corporation
- 15.3.16. ICU Medical, Inc.
- 15.3.17. Medtronic PLC
- 15.3.18. Merck KGaA
- 15.3.19. Nipro Medical Corporation
- 15.3.20. Qiagen N.V.
- 15.3.21. Retractable Technologies, Inc.
- 15.3.22. Siemens Healthineers AG
- 15.3.23. Terumo Corporation
- 15.3.24. Thermo Fisher Scientific Inc.
- 15.3.25. Zymo Research Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
